| Document |
Document Title |
|
JP2687209B2 |
A novel steroid of the formula I wherein X is methylene and R is an optionally substituted carbocyclic aryl or heterocyclic aryl or optionally substituted vinyl or ethynyl or X is a simple bond or -S- and R is optionally substituted carb...
|
|
JP2684180B2 |
PCT No. PCT/FR87/00096 Sec. 371 Date Nov. 25, 1987 Sec. 102(e) Date Nov. 25, 1987 PCT Filed Mar. 26, 1987 PCT Pub. No. WO87/05908 PCT Pub. Date Oct. 8, 1987. (I) (II) (III) (IV) (V) (VI) Products having the formula (I) wherein R1 is an a...
|
|
JP2675418B2 |
Compounds of formula (I) in which X<1>, X<2> and X<3> are hydrogen, halogen, CF3, C1-6alkyl, OH, C1-6alkoxy, CN, NO2, N(R<1>)2, CHO or CO2R<1>; A is O or S, n is 0 or 1, R<1> is H or C1-8alkyl and R<3> is alpha -H, alpha -OH, or alpha -a...
|
|
JPH09511214A |
The present invention relates to DELTA 16 unsaturated steroids which are useful as steroid C17-20 lyase inhibitors.
|
|
JP2667418B2 |
PCT No. PCT/FR87/00244 Sec. 371 Date Feb. 24, 1988 Sec. 102(e) Date Feb. 24, 1988 PCT Filed Jun. 24, 1987 PCT Pub. No. WO88/00202 PCT Pub. Date Jan. 14, 1988.Compounds obtained from the associative synthesis of sulfur-containing or sulfu...
|
|
JP2660413B2 |
Compounds (I): in which: R1 is hydrogen or methyl, R2 is methyl or ethyl, the nuclei A, B, C and D carry optionally one or more double bonds and are optionally substituted by one or more functional groups or by one or more atoms or radic...
|
|
JP2660404B2 |
1. The products of formula I : see diagramm : EP0245170,P90,F1 in which R1 represents an alkynyl radical having from 2 to 8 carbon atoms optionally substituted by a radical selected from the radicals, hydroxyl, halogen, trialkylsilyl, al...
|
|
JPH09509959A |
Compounds having a broad range of antimicrobial activity generally have a structure including a steroid nucleus with a cationic, preferably polyamine, side chain (X) and an anionic side chain (Y). The invention is also directed to compou...
|
|
JP2652007B2 |
PCT No. PCT/FR87/00096 Sec. 371 Date Nov. 25, 1987 Sec. 102(e) Date Nov. 25, 1987 PCT Filed Mar. 26, 1987 PCT Pub. No. WO87/05908 PCT Pub. Date Oct. 8, 1987. (I) (II) (III) (IV) (V) (VI) Products having the formula (I) wherein R1 is an a...
|
|
JP2646568B2 |
The invention provides the use of a compound of the formula [E-DHC] (I) or a non-toxic pharmaceutically acceptable salt thereof, wherein [E] is an estrogen and [DHC] is the reduced, biooxidizable, blood-brain barrier-penetrating, lipoida...
|
|
JP2642089B2 |
Bile acid derivatives of the formula I W-X-G in which G is a bile acid residue, W is an active substance portion of a medicament and X is a linker between bile acid residue and active substance portion, are outstandingly suitable for int...
|
|
JP2642090B2 |
Bile acid derivatives of the formula I W-X-G in which G is a bile acid residue, W is an active substance portion of a medicament and X is a linker between bile acid residue and active substance portion, are outstandingly suitable for int...
|
|
JPH09507248A |
This invention is directed to novel purine-based compounds for inclusion into oligonucleotides. The compounds of the invention, when incorporated into oligonucleotides are especially useful as "antisense" agents-agents that are capable o...
|
|
JPH09502984A |
Urethane-containing amino steroids having the general chemical formula: wherein a, b, R1, R2, R3, R4, R14 and Z are as defined in the specification. Also disclosed are pharmaceutical composition and the use of the compounds/composition i...
|
|
JP2587034B2 |
Centrally acting drug species are site-specifically/sustainedly delivered to the brain by administering to a patient in need of such treatment a therapeutically effective amount of the target drug species [D] tethered to a reduced, blood...
|
|
JP2580091B2 |
Compositions and methods for modulating the activity of RNA and DNA are disclosed. In accordance with preferred embodiments, antisense compositions are prepared comprising targeting and reactive portions. Reactive portions which act, alt...
|
|
JP2575460B2 |
|
|
JPH0912593A |
To obtain the new derivatives comprising a specific 17- hydroxyiminoalkylcyclopentane perhydrophenanthrene derivative, etc., having affinity to Na+, K+-ATPase receptors, and useful for the therapy of cardiac failures, hypertension, etc. ...
|
|
JP2568306B2 |
Bile acid derivatives of the formula I W-X-G in which G is a bile acid residue, W is an active substance portion of a medicament and X is a linker between bile acid residue and active substance portion, are outstandingly suitable for int...
|
|
JP2563587B2 |
The present invention concerns novel compounds having the general formula wherein R<1>, R<2> and R<3> are selected from the group consisting of hydrogen or lower alkyl having 1-4 carbon atoms, wherein R<2> and R<3> together with the N at...
|
|
JP2560370B2 |
|
|
JP2550777B2 |
|
|
JP2545522B2 |
This invention provides novel tetrahydro steroids which are useful in inhibiting angiogenesis and have the following structure: A compound of the formula: wherein R1 is beta -CH3 or beta -CH2H5; wherein R2 is H, and R3 is =0, -OH, -0-alk...
|
|
JPH08245687A |
PURPOSE: To obtain the subject new compound which is an N-substituted carbamide derivative of 3-carboxy-androst-3,5-diene and useful for treatment, etc., of acne, seborrhoica, hirsutism, alopecia, etc., as a testosterone 5α-reductase in...
|
|
JPH08508727A |
PCT No. PCT/EP94/00937 Sec. 371 Date Oct. 6, 1995 Sec. 102(e) Date Oct. 6, 1995 PCT Filed Mar. 24, 1994 PCT Pub. No. WO94/22898 PCT Pub. Date Oct. 13, 1994Glucocorticoids of general formula IR-Val-O-GC (II),are described, in which O-GC i...
|
|
JPH08508506A |
PCT No. PCT/DE94/00316 Sec. 371 Date Nov. 6, 1995 Sec. 102(e) Date Nov. 6, 1995 PCT Filed Mar. 18, 1994 PCT Pub. No. WO94/24146 PCT Pub. Date Oct. 27, 1994Novel androgens having one or more substituents providing radical trapping propert...
|
|
JP2514778B2 |
PURPOSE: To obtain a new compound, having excellent inhibiting action on testosterone 5α-reductases and low toxicity and useful as a preventing and therapeutic agent for diseases caused by an excess of 5α-dihydrotestosterone, especiall...
|
|
JPH08503471A |
Invented are 17 alpha and 17 beta -substituted acyl-3-carboxy-3,5-diene analogues of steroidal synthetic compounds, pharmaceutical compositions containing these compounds, and methods for using these compounds to inhibit steroid 5- alpha...
|
|
JPH0826062B2 |
9-Alpha-hydroxy- steroids (I) contg. a D-ring of formula (A) are new; R2 = ethynyl (provided R5 is not acetoxy if R4 = H), haloethynyl, opt. protected OH, cyano, 1'-Ra-ethenyl; or 1',1'-trimethylene dithio-ethyl; Ra = 1-6C alkoxy or alky...
|
|
JPH0813274B2 |
Compositions and methods are provided for the treatment and diagnosis of diseases amenable to modulation of the production of selected proteins. In accordance with preferred embodiments, oligonucleotides and oligonucleotide analogs are p...
|
|
JPH07110851B2 |
The invention concerns new aminoalkylmaleimides of the general formula I (I) in which R1 and R2 are the same or different and represent hydrogen or a C1-C4 alkyl group and A represents a straight-chain or branched, saturated or unsaturat...
|
|
JPH0791312B2 |
1. The products of general formula I : see diagramm : EP0237397,P31,F2 in which R represents : - either a hydrogen atom, - or an alkyl, alkenyl or alkynyl radical having at most 8 carbon atoms possibly substituted by a radical chosen fro...
|
|
JPH07242548A |
PURPOSE: To obtain a medicine tending to concentrate to the bone tissue, having both bone resorption-suppressive activity and osteogenesis-promotive activity, thus useful as an osteopathy therapeutic agent, containing a compound formed b...
|
|
JPH07508034A |
PCT No. PCT/US93/04633 Sec. 371 Date Mar. 20, 1995 Sec. 102(e) Date Mar. 20, 1995 PCT Filed May 17, 1993 PCT Pub. No. WO93/23038 PCT Pub. Date Nov. 25, 1993Novel amino substituted 4-azasteroid 5 alpha -reductase inhibitors of formula (I)...
|
|
JPH07507792A |
PCT No. PCT/HU93/00035 Sec. 371 Date Dec. 8, 1994 Sec. 102(e) Date Dec. 8, 1994 PCT Filed Jun. 8, 1993 PCT Pub. No. WO93/25570 PCT Pub. Date Dec. 23, 1993Novel, therapeutically active 21-aminosteroids of formula (I) (I) with pregnane ske...
|
|
JPH07228593A |
PURPOSE: To obtain a new compound useful as an antibacterial or anti- inflammatory agent. CONSTITUTION: This new compound as a steroid derivative has the structure expressed by formula I (R is H, methyl or OH), where the carboxyl group o...
|
|
JPH07507551A |
PCT No. PCT/HU93/00034 Sec. 371 Date Dec. 8, 1994 Sec. 102(e) Date Dec. 8, 1994 PCT Filed Jun. 8, 1993 PCT Pub. No. WO93/25539 PCT Pub. Date Dec. 23, 1993An intermediate compound is disclosed that is useful in the preparation of a lipid-...
|
|
JPH0772193B2 |
A novel steroid of the formula I wherein X is methylene and R is an optionally substituted carbocyclic aryl or heterocyclic aryl or optionally substituted vinyl or ethynyl or X is a simple bond or -S- and R is optionally substituted carb...
|
|
JPH07196684A |
PURPOSE: To provide new steroid compounds of substituted 2β-morpholino- androstane derivatives having very potent anaesthetic activity and fast onset times and ideal sleep duration vs. recovery to full coordination profiles which are us...
|
|
JPH07506575A |
Inhibitors of testosterone 5 alpha -reductase activity, for example those of formula: wherein novel substituents are provided at the R4, R6, R7, R17 alpha and/or R17 beta positions are useful for the treatment of diseases whose progress ...
|
|
JPH07506582A |
Competitive progesterone antagonists, including two novel steroids, viz., 11beta,19-[4-(cyanophenyl)-o-phenylene]-17beta-hydroxy-17alp
ha-(3-hydroxyprop-1(Z)-enyl)-4-androsten-3-one and 11beta,19-[4-(3-pyridinyl)-o-phenylene]-17beta-hydr...
|
|
JPH07506363A |
PCT No. PCT/US93/03778 Sec. 371 Date Oct. 28, 1994 Sec. 102(e) Date Oct. 28, 1994 PCT Filed Apr. 22, 1993 PCT Pub. No. WO93/22333 PCT Pub. Date Nov. 11, 1993Invented are 17 alpha and 17 beta -substituted acyl-3-carboxy aromatic A ring an...
|
|
JPH0755960B2 |
New processes for preparing new steroid derivatives including ergosta-1,5,7,22-tetraen-3 beta -ol, 1 alpha -hydroxy-ergosteryl diacetate, etc. which are useful intermediates in the synthesis of 1 alpha -hydroxy vitamin D2. The processes ...
|
|
JPH07505138A |
The invention provides an improved process for the preparation of a halogenated steroidal diene. The process involves the simultaneous transformation of the steroidal 3-one to 3-halo and 17-carboxylic acid to 17-carboxamide in a single r...
|
|
JPH07505140A |
Invented is an improved process for the preparation of substituted steroidal dienes. Also invented are novel intermediates used in said process.
|
|
JPH0753751B2 |
2-Morpholinyl-androstane derivs. of fomrula (I), their mono- and bis-quat. ammonium cpds. and the acid addn. salts of (I) or its mono-quat. ammonium cpds. are new. In the formula, R1 = H or 1-12C opt. substd. acyl; R2 = H or 1-12C acyl; ...
|
|
JPH07504900A |
Viral infection is inhibited in mammals by administration of metabolically stable, non-toxic 2',5'-oligoadenylate (2-5A) derivatives that have a dual therapeutic effect. The compounds activate the intracellular latent 2-5A dependent endo...
|
|
JPH07503708A |
Novel glycosylated steroid derivatives for facilitating the transport of compounds across biological membranes are disclosed. A novel process for efficient synthesis of these glycosylated steroid derivatives, using activated glycosyl sul...
|
|
JPH07101978A |
PURPOSE: To obtain a new cholesterol derivative, capable of acting as an anchor on a lipid membrane and binding the lipid membrane to a biological substance and useful for immunodiagnosis, medical applications, medicines, etc., by conden...
|
|
JPH07503466A |
PCT No. PCT/US93/00211 Sec. 371 Date Jul. 25, 1994 Sec. 102(e) Date Jul. 25, 1994 PCT Filed Jan. 26, 1993 PCT Pub. No. WO93/15103 PCT Pub. Date Aug. 5, 1993.Novel steroids having a 9 alpha -hydroxy or a 9 alpha -carbonate substituent can...
|
